New home prices in China’s biggest cities record first rise in 10 months



Mainland China’s first-tier home prices edged up 0.2 per cent in March, rising after nine months of losses and no change in February, but it is too soon to declare the property market stable without sustained improvement in homebuying demand, according to analysts.

Compared with a month earlier, March home prices were flat in Beijing, rose 0.3 per cent in Shanghai and Guangzhou, and gained 0.2 per cent in Shenzhen, according to data released by the National Bureau of Statistics (NBS) on Thursday.

Among the 70 large and medium-sized cities tracked nationwide, new home prices recorded month-on-month increases in 14, up from 10 in February, the NBS said.

“We believe it remains premature to conclude that this signals a broader stabilisation in China’s housing market,” said Edward Chan, a Greater China analyst at S&P Global Ratings. “It will be important to observe whether the price improvements are sustainable.”

The fact that the property market had not worsened could be considered a positive outcome, with stable but “not overwhelming” recovery and determined policy support, said Griffin Chan, an analyst at Citi Research, in a report on Thursday.

“Most investors do not anticipate a substantial turnaround and need more conviction for stabilising prices in key cities” before increasing investments in the sector, Chan said. “Given sales recovery started in the first quarter and continued in April, we [believe that] sector correction in March offered a good opportunity to add property names in April.”

  • Related Posts

    Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market

    Eight mainland China-based companies – five of them biotech firms – passed listing hearings on the Hong Kong stock market in April, clearing the way for them to tap the…

    Continue reading
    Multinational pharmaceutical companies to benefit from new China guidelines: analysts

    The State Council, China’s cabinet, has published guidelines on innovative drug pricing that a bank analyst has described as “the most significant” in a decade, as they aim to reward…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *